Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Through implementation of this testing it is hoped that pharmaceutical drug treatments can deviate from what is dubbed as the "one-dose-fits-all" approach. It attempts to eliminate the trial-and-error method of prescribing, allowing physicians to take into consideration their patient's genes, the functionality of these genes, and how this may affect the efficacy of the patient's current or future treatments (and where applicable, provide an explanation for the failure of past treatments).

Our cardiac genotyping panel consists of eight MDx assays that identify genetic biomarkers which regulate individual metabolic compatibility with clopidogrel (Plavix), warfarin (Coumadin), ticragrelor (Brillinita) and beta blockers 

• CYP450 2C19 Clopidrogel (Plavix)
• CYP450 2C9/VKORC1 Warfarin Resistance (Coumadin)
• CYP450 2D6 Beta Blocker Resistance 
• CYP450 3A4/3A5 Protease Inhibitors  
• SLCO1B1 Statins
• Factor II Prothrombin Deficiency
• Factor V Leiden Inherited Thrombophilia
• MTHFR Hyperhomocysteinemia
• COMT  Catecholamine
• ApoE Lipoprotein
• CYP1A2
• CYP2B6
• SLCO1B1

Genetic testing now makes it easier than ever for physicians to determine which drugs are most compatible with their patient's genetic make up, before even the first dose. Our goal is to deliver industry-leading diagnostic services to physicians and their patients. We provide state-of-the-art genotype/phenotype pharmacogenomic reports, secure online test requisitioning and patient laboratory test results.